Scancell Holdings PLC's (LON:SCLP) Cliff Holloway speaks to Proactive London's Andrew Scott after revealing it's begun a research programme to develop a vaccine for the coronavirus.
The project, to be led by the company’s chief scientific officer Lindy Durrant, will aim to use the company’s clinical expertise in cancer to produce a cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against coronavirus.